Dan Minion is a patent litigator who focuses on Hatch-Waxman litigation, chemicals litigation, and contested proceedings before the U.S. Patent and Trademark Office. In addition to first-chair litigation before District Courts, he has argued on behalf of major pharmaceutical companies at the U.S. Court of Appeals for the Federal Circuit and the Patent Trial and Appeal Board (for both petitioner and patent owner). Dan has counseled on a wide range of pharmaceuticals in a variety of formulations used to treat breast and prostate cancer, renal disease, hypertension, arrhythmias, chronic pain, epilepsy, hormonal and genetic disorders, osteoporosis, Alzheimer’s, and multiple sclerosis.
Before joining Venable, Dan spent his entire career in private practice at Fitzpatrick, Cella, Harper & Scinto.
Prior to law school, Dan worked as a medicinal chemist at Agouron Pharmaceuticals and obtained a master’s degree in organic chemistry for his synthetic studies on the viridin family of kinase inhibitors.